Zenuzolac: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -200% 1 90 Improvement, Studies, Patients Relative Risk Mortality -200% 1 90 Hospitalization 1% 1 90 RCTs -200% 1 90 Late -200% 1 90 Zenuzolac for COVID-19 c19early.org December 2025 Favorszenuzolac Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -200% 3.00 [0.32-28.3] death 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk All studies -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk 1 zenuzolac COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Effect extraction pre-specified(most serious outcome) Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -200% 3.00 [0.32-28.3] 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk All studies -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk 1 zenuzolac COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) 1% 0.99 [0.88-1.11] hosp. time 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment 1% 0.99 [0.88-1.11] 46 (n) 44 (n) 1% lower risk All studies 1% 0.99 [0.88-1.11] 46 (n) 44 (n) 1% lower risk 1 zenuzolac COVID-19 hospitalization result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -200% 3.00 [0.32-28.3] death 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk All studies -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk 1 zenuzolac COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Effect extraction pre-specified(most serious outcome) Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -1% 1.01 [0.25-4.09] no recov. 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Late treatment -1% 1.01 [0.25-4.09] 46 (n) 44 (n) 1% higher risk All studies -1% 1.01 [0.25-4.09] 46 (n) 44 (n) 1% higher risk 1 zenuzolac COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -200% 3.00 [0.32-28.3] death 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk All studies -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk 1 zenuzolac COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Effect extraction pre-specified(most serious outcome) Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -200% 3.00 [0.32-28.3] 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk All studies -200% 3.00 [0.32-28.3] 46 (n) 44 (n) 200% higher risk 1 zenuzolac COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Favors zenuzolac Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kane (DB RCT) -200% 3.00 [0.32-28.3] death 46 (n) 44 (n) Improvement, RR [CI] Treatment Control Kane (DB RCT) -196% 2.96 [0.12-70.7] death 1/46 0/44 Kane (DB RCT) -205% 3.05 [0.13-72.8] death 1/42 0/44 Kane (DB RCT) -1% 1.01 [0.25-4.09] no recov. 46 (n) 44 (n) Kane (DB RCT) -43% 1.43 [0.25-8.18] no recov. 3/46 2/44 Kane (DB RCT) 48% 0.52 [0.05-5.56] no recov. 1/42 2/44 Kane (DB RCT) 1% 0.99 [0.88-1.11] hosp. time 46 (n) 44 (n) Kane (DB RCT) 1% 0.99 [0.84-1.16] hosp. time 46 (n) 44 (n) Kane (DB RCT) 1% 0.99 [0.83-1.18] hosp. time 42 (n) 44 (n) Zenuzolac COVID-19 outcomes c19early.org December 2025 Favors zenuzolac Favors control